Compositions and Methods for Treating Cancer with DuoCARs
AssigneeLentigen Technology, Inc.
InventorsRimas Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
Life of this patent
Estimating the term…
Abstract
Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
Claims26
An immunotherapy composition comprising at least two vectors, each vector encoding a functional chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain, a transmembrane domain, and one or more non-identical intracellular signaling motifs, wherein the at least one extracellular antigen binding domain of each CAR encoded by the vectors are non-identical, and whereby the combination of vectors results in the expression of two or more non-identical extracellular antigen binding domains.
-5. (canceled)
-8. (canceled)
(canceled)
(canceled)
-22. (canceled)
A pharmaceutical composition comprising an antitumor effective amount of a population of human lymphocyte cells, wherein the population of human lymphocyte cells comprises cells comprising two or more vectors;
- wherein each vector encodes a functional chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain, at least one transmembrane domain, at least one linker domain, and at least one intracellular signaling motif;
- wherein the at least one extracellular antigen binding domain of each CAR encoded by the vectors are non-identical.
-31. (canceled)
A method of treating a subject having a cancer, the method comprising administering to the subject a pharmaceutical composition comprising an antitumor effective amount of a population of human lymphocyte cells, wherein the population of human lymphocyte cells comprises cells comprising two or more vectors;
- wherein each vector encodes a functional chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling motif;
- wherein the at least one extracellular binding domain of each CAR encoded by the vectors are non-identical.
Dependencies are inferred from the claim text.